with a novel lowdose paclitaxelcoated balloon was superior to PTA with standard angioplasty alone in moderately long lesions in the SFA andor popliteal arteries D ata were similar to the ID: 1006524
Download Presentation The PPT/PDF document "Percutaneous transluminal angioplasty (P..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Percutaneous transluminal angioplasty (PTA) with a novel low-dose paclitaxel-coated balloon was superior to PTA with standard angioplasty alone in moderately long lesions in the SFA and/or popliteal arteries Data were similar to the LEVANT 2 trial, which used a different balloon but the same drug (differences are in balloon design and dose of paclitaxel)Standard PTA(n = 100)DCB(n = 200)ILLUMENATEPrimary efficacy outcome, clinically driven target lesion revascularization: DCB vs. standard balloon: 93.6% vs. 87.3%, p < 0.05 Primary patency at 12 months: 82.3% vs. 70.9%, p < 0.05Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon angioplasty with a paclitaxel drug-coated balloon (DCB) or standard balloon. They were followed for 12 months.ResultsConclusionsPresented by Dr. Sean Lyden at TCT 2016 Primary endpoint(p < 0.05)%